Environmental

RDY’s R&D intensity supports process and formulation efficiency, which can lower resource waste versus peers with lower innovation spend in generics.

The company’s capital structure is relatively conservative, reducing balance-sheet pressure that can otherwise constrain environmental compliance investments compared with more leveraged peers.

No major environmental controversies or high-emissions disclosures were provided, so the available evidence suggests a neutral-to-better-than-peer environmental risk profile.

As a pharmaceutical manufacturer, RDY still faces industry-wide exposure to energy, water, and waste management requirements, but nothing in the supplied metrics indicates a structural disadvantage versus peers.

Social

RDY’s low stock-based compensation intensity suggests restrained dilution and a comparatively disciplined approach to employee incentives versus peers with heavier equity compensation.

Higher R&D spending relative to revenue can support product quality, access, and therapeutic continuity, which is socially favorable in a regulated healthcare industry.

The absence of provided labor, safety, or product-quality controversies limits evidence of peer-relative social weakness, leaving the profile broadly in line with stronger operators.

As a generic-drug company, RDY remains exposed to supply continuity and patient-access expectations, but the available data do not show a material social gap versus peers.

Governance

RDY’s low debt-to-equity ratio indicates less creditor pressure on management, which generally supports governance flexibility versus more highly levered peers.

Net debt to EBITDA below 1.0 suggests a comparatively disciplined capital structure, reducing refinancing risk that can amplify governance strain in stressed periods.

The very low stock-based compensation ratio points to limited compensation-related dilution, which is often viewed more favorably than peer practices with heavier equity awards.

No filing-based governance controversies were provided, so the available evidence supports a solid but not exceptional governance position relative to peers.

Overall Score

RDY appears modestly stronger than peers overall, driven by disciplined capital structure, restrained compensation dilution, and supportive R&D intensity across ESG dimensions.

Score Driver: Disciplined Balance Sheet And Low Compensation Dilution Versus Peers